Elicio Therapeutics, INC 10-Q quarterly reports

Elicio Therapeutics reports a decrease in R&D expenses for Q1 2026, alongside an increase in G&A costs, and highlights ongoing concerns about its ability to continue as a going concern.

Elicio Therapeutics reports reduced net losses in Q3 2025 but faces substantial doubt about its ability to continue as a going concern due to dwindling cash reserves.

Elicio Therapeutics reported increased net losses and a going concern warning, despite recent capital raises and positive clinical trial safety data for ELI-002 7P.

Elicio Therapeutics reports a net loss of $11.2 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Elicio Therapeutics reports a net loss of $18.8 million for the third quarter of 2024, alongside updates on clinical trials and financial activities.

Elicio Therapeutics, a clinical-stage biotechnology company, announced its second quarter 2024 financial results, highlighting ongoing clinical development and financial challenges.

Elicio Therapeutics reports a net loss of $11.8 million for the first quarter of 2024, with ongoing development of its cancer immunotherapies.